A PCR amplicon–based SARS-CoV-2 replicon for antiviral screening
Preprint
Abstract
The development of specific antiviral compounds to SARS-CoV-2 is an urgent task. One of the obstacles for the antiviral development is the requirement of biocontainment because infectious SARS-CoV-2 must be handled in a biosafety level-3 laboratory. Replicon, a non-infectious self-replicative viral RNA, could be a safe and effective tool for antiviral screening; however, SARS-CoV-2 replicon has not been reported yet. Herein, we generated a PCR-based SARS-CoV-2 replicon. Eight fragments covering the entire SARS-CoV-2 genome except S, E, and M genes were amplified with HiBiT-tag sequence by PCR. The amplicons were ligated and in vitro transcribed to RNA. The cells electroporated with the replicon RNA showed more than 3,000 times higher luminescence than MOCK control cells at 24 hours post-electroporation, indicating robust viral translation and RNA replication. The replication was drastically inhibited by remdesivir, an RNA polymerase inhibitor for SARS-CoV-2. The IC 50 of remdesivir in this study was 0.29 μM, generally consistent to the IC 50 obtained using infectious SARS-CoV-2 in a previous study (0.77 μM). Taken together, this system could be applied to the safe and effective antiviral screening without using infectious SARS-CoV-2. Because this is a transient replicon, further improvement including the establishment of stable cell line must be achieved.Keywords
All Related Versions
- Published version: Scientific Reports, 11 (1), 1.
This publication has 18 references indexed in Scilit:
- The molecular virology of coronavirusesJournal of Biological Chemistry, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- An Infectious cDNA Clone of SARS-CoV-2Cell Host & Microbe, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirusProceedings of the National Academy of Sciences, 2013
- Construction of a non-infectious SARS coronavirus replicon for application in drug screening and analysis of viral protein functionBiochemical and Biophysical Research Communications, 2008
- Derivation of a novel SARS–coronavirus replicon cell line and its application for anti-SARS drug screeningVirology, 2007
- Construction of a Severe Acute Respiratory Syndrome Coronavirus Infectious cDNA Clone and a Replicon To Study Coronavirus RNA SynthesisJournal of Virology, 2006
- Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirusProceedings of the National Academy of Sciences, 2003